Akums Drugs & Pharmaceuticals Ltd
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
- Market Cap ₹ 9,089 Cr.
- Current Price ₹ 578
- High / Low ₹ 1,176 / 405
- Stock P/E 27.9
- Book Value ₹ 194
- Dividend Yield 0.00 %
- ROCE 16.4 %
- ROE 17.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 49.2% CAGR over last 5 years
Cons
- Stock is trading at 2.98 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has a low return on equity of 13.1% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | |
| 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | |
| Operating Profit | 124 | 144 | 174 | 237 | -89 | 294 | 123 | 464 |
| OPM % | 8% | 9% | 7% | 9% | -2% | 8% | 3% | 11% |
| 6 | 6 | 26 | 12 | 7 | 15 | 8 | 69 | |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% |
| 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | |
| EPS in Rs | 366.55 | 523.23 | 335.61 | 949.10 | -35.30 | 6.63 | -0.28 | 21.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 4% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 49% |
| 3 Years: | 50% |
| TTM: | 1377% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 13% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 |
| 255 | 213 | 175 | 97 | 395 | 619 | 565 | 88 | |
| 293 | 318 | 1,140 | 1,170 | 2,033 | 1,905 | 2,229 | 978 | |
| Total Liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,113 |
| 444 | 501 | 645 | 834 | 1,021 | 1,097 | 1,191 | 1,401 | |
| CWIP | 0 | 11 | 57 | 87 | 31 | 103 | 195 | 160 |
| Investments | 0 | 18 | 6 | 19 | 0 | 0 | 0 | 0 |
| 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,553 | |
| Total Assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,113 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 72 | 89 | 28 | 135 | 32 | 177 | 498 | 465 | |
| -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | |
| 66 | 37 | 233 | -95 | 236 | 125 | -108 | 73 | |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 |
| Inventory Days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 |
| Days Payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 |
| Cash Conversion Cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 |
| Working Capital Days | 78 | 73 | 75 | 77 | 84 | 89 | 76 | 73 |
| ROCE % | 14% | 20% | -16% | 22% | 2% | 16% |
Documents
Announcements
-
Intimation Of Approval Of Revised Notice Of Annual General Meeting ('AGM')
7 Jun - Revised AGM notice includes agenda for Independent Director appointment.
-
Intimation Of Appointment Of Additional Director (Non-Executive- Independent)
4 Jun - Appointment of Mr. Anil Amin as Independent Additional Director from June 4, 2025, for five years.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Jun - Akums FY25 Q4 earnings: flat revenue, 9% volume growth, EUR200M contract, INR300Cr capex planned.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 May - Audio recording of Q4 FY25 and FY25 earnings call shared on May 27, 2025.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 27 May
Concalls
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Sep 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPTREC
Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.